ZyVersa Therapeutics Offers Hope to 32 Million Americans Living with Kidney Disease
Clinical stage biopharmaceutical company, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), has received Institutional Review Board (IRB) approval of its Phase 2a clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease. The company’s study is on track to begin in the first half of 2024.
ZyVersa’s clinical trial is a first-in-human trial for VAR 200. The company’s preclinical data for VAR 200 demonstrated that reduced cholesterol and lipid levels in the kidneys’ filtration system, protected against kidney injury and fibrosis, and significantly reduced protein in the urine (proteinuria) in animal models.
“A large body of evidence reinforces the importance of addressing kidney accumulation of cholesterol and lipids to help attenuate progression of chronic kidney disease, which affects over 35 million adults in the United States,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President.
“Currently, over 130,000 patients with kidney disease progress to renal failure each year, and more than 800,000 patients are living with renal failure requiring dialysis or transplant to sustain life. We are excited about the potential of Cholesterol Efflux MediatorTM VAR 200 to protect against kidney injury and reduce kidney disease progression.”
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit www.zyversa.com.
